Cynata Therapeutics Toekomstige groei

Future criteriumcontroles 2/6

De verwachting is dat Cynata Therapeutics de winst en omzet met respectievelijk 34.1% en 70.4% per jaar zal laten groeien, terwijl de winst per aandeel naar verwachting zal groeien met 54.2% per jaar.

Belangrijke informatie

34.1%

Groei van de winst

54.2%

Groei van de winst per aandeel

Biotechs winstgroei	15.2%
Inkomstengroei	70.4%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Low
Laatst bijgewerkt	05 Aug 2024

Recente toekomstige groei-updates

Recent updates

We're Interested To See How Cynata Therapeutics (ASX:CYP) Uses Its Cash Hoard To Grow

Feb 02

We Think Cynata Therapeutics (ASX:CYP) Can Easily Afford To Drive Business Growth

Sep 09

Here's Why We're Not At All Concerned With Cynata Therapeutics' (ASX:CYP) Cash Burn Situation

May 26

Here's Why We're Not Too Worried About Cynata Therapeutics' (ASX:CYP) Cash Burn Situation

Dec 31

We're Not Worried About Cynata Therapeutics' (ASX:CYP) Cash Burn

Aug 11

Winst- en omzetgroeiprognoses

ASX:CYP - Toekomstschattingen van analisten en financiële gegevens uit het verleden (AUD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
6/30/2026	7	-5	-4	-4	1
6/30/2025	1	-8	-8	-8	1
6/30/2024	2	-10	-10	-10	N/A
3/31/2024	2	-12	-11	-11	N/A
12/31/2023	2	-14	-12	-12	N/A
9/30/2023	2	-14	-13	-13	N/A
6/30/2023	2	-14	-14	-14	N/A
3/31/2023	2	-12	-12	-12	N/A
12/31/2022	3	-9	-10	-10	N/A
9/30/2022	5	-7	-7	-7	N/A
6/30/2022	8	-5	-3	-3	N/A
3/31/2022	8	-5	-2	-2	N/A
12/31/2021	8	-4	-1	-1	N/A
9/30/2021	5	-6	-3	-3	N/A
6/30/2021	2	-8	-5	-5	N/A
3/31/2021	2	-7	-5	-5	N/A
12/31/2020	3	-6	-5	-5	N/A
9/30/2020	5	-5	-4	-4	N/A
6/30/2020	7	-4	-3	-3	N/A
3/31/2020	6	-6	-5	-5	N/A
12/31/2019	4	-8	-7	-7	N/A
9/30/2019	3	-8	-7	-7	N/A
6/30/2019	1	-8	-7	-7	N/A
3/31/2019	1	-7	-6	-6	N/A
12/31/2018	1	-6	-5	-5	N/A
9/30/2018	1	-5	-4	-4	N/A
6/30/2018	1	-5	-4	-4	N/A
3/31/2018	1	-5	N/A	-4	N/A
12/31/2017	1	-5	N/A	-5	N/A
9/30/2017	2	-5	N/A	-4	N/A
6/30/2017	2	-5	N/A	-4	N/A
3/31/2017	2	-4	N/A	-3	N/A
12/31/2016	2	-3	N/A	-2	N/A
9/30/2016	1	-4	N/A	-3	N/A
6/30/2016	1	-5	N/A	-4	N/A
3/31/2016	1	-5	N/A	-4	N/A
12/31/2015	1	-5	N/A	-4	N/A
9/30/2015	1	-4	N/A	-4	N/A
6/30/2015	0	-4	N/A	-3	N/A
3/31/2015	0	-3	N/A	-2	N/A
12/31/2014	0	-3	N/A	-2	N/A
9/30/2014	0	-3	N/A	-2	N/A
6/30/2014	0	-3	N/A	-2	N/A
3/31/2014	0	-3	N/A	-1	N/A
12/31/2013	0	-2	N/A	-1	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat CYP de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat CYP de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat CYP de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van CYP ( 70.4% per jaar) zal naar verwachting sneller groeien dan de markt Australian ( 5.6% per jaar).

Hoge groei-inkomsten: De omzet van CYP ( 70.4% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van CYP naar verwachting over 3 jaar hoog zal zijn

Cynata Therapeutics Toekomstige groei

Future criteriumcontroles 2/6

Belangrijke informatie

Recente toekomstige groei-updates

Price target decreased to AU$2.00

Recent updates

Cynata Therapeutics Limited, Annual General Meeting, Nov 19, 2024

Here's Why We're Watching Cynata Therapeutics' (ASX:CYP) Cash Burn Situation

New major risk - Financial position

Will Cynata Therapeutics (ASX:CYP) Spend Its Cash Wisely?

Cynata Therapeutics Limited Completes Patient Enrolment in CYP-006TK Diabetic Foot Ulcer Clinical Trial

Cynata Therapeutics Limited Announces Updates on Phase 2 Clinical Trial of CYP-001

New minor risk - Financial position

We're A Little Worried About Cynata Therapeutics' (ASX:CYP) Cash Burn Rate

Cynata Therapeutics Limited Announces Resignation of David Atkins as Director

New major risk - Financial position

Cynata Therapeutics Limited Announces Management Appointments

We're Interested To See How Cynata Therapeutics (ASX:CYP) Uses Its Cash Hoard To Grow

Cynata Therapeutics Limited Receives IRB Approval for Proposed aGvHD Phase 2 Clinical Trial

Cynata Therapeutics Limited Receives Notice of Acceptance from IP Australia for Novel Application of Cymerus MSCs

LUMC to Fund New Clinical Trial of Cynata's Cymerus™ MSCs in Kidney Transplantation

Cynata Therapeutics Limited Receives Notice of Allowance for Australia & Canada Cymerus Patents

Cynata Therapeutics Limited Announces Successful Completion of Planned DSMB Review of DFU Trial

Cynata Therapeutics Limited, Annual General Meeting, Nov 22, 2022

Cynata Therapeutics Limited Receives Grant Award to Fund Study of Cynata Mscs in Heart Disease from Australian Government National Health and Medical Research Council

We Think Cynata Therapeutics (ASX:CYP) Can Easily Afford To Drive Business Growth

Cynata Therapeutics Limited Appoints Janine Rolfe as Independent Non-Executive Director, Effective 1 September 2022

Cynata Therapeutics Limited Announces Preclinical Study Showing Optimisation of CymerusTM MSCs for Coronary Artery Disease Published in Leading Peer-Reviewed Journal

Cynata Therapeutics Limited Receives Notice of Allowance from US Patent Office for Use of the Cymerus MSCs in Asthma

Cynata Therapeutics Limited Announces the Completion of A Pre-Clinical Study That Has Provided Further Evidence in Support of the Highly Potent Anti-Inflammatory Effects of Cynata's Proprietary Cymerus MSCs

Cynata Therapeutics Limited Adds New Site for MEMD Clinical Trial

United States Food and Drug Administration Clears IND for Cynata Therapeutics Limited's Phase 2 Clinical Trial of CYP-001 in GvHD

Here's Why We're Not At All Concerned With Cynata Therapeutics' (ASX:CYP) Cash Burn Situation

Price target decreased to AU$2.00

Cynata Therapeutics Limited Advances Clinical Trial in Diabetic Foot Ulcers

Cynata Therapeutics Limited Receives Decision to Grant A Patent in Japan

Cynata Therapeutics Limited Receives Decision to Grant A Patent in Japan

Here's Why We're Not Too Worried About Cynata Therapeutics' (ASX:CYP) Cash Burn Situation

Cynata Therapeutics Limited Commences DFU Clinical Trial

We're Not Worried About Cynata Therapeutics' (ASX:CYP) Cash Burn

Cynata Therapeutics Limited Receives Approval by the Central Adelaide Local Health Network Human Research Ethics Committee to Commence A Clinical Trial

Cynata Therapeutics Limited Progresses Toward Clinical Trial in Diabetic Foot Ulcers

Cynata Therapeutics Limited Announces First Patient Enrolled in Cynata Mend Clinical Trial

Cynata Therapeutics Limited to Investigate New Study of the High Potency of Cymerus MSCs

New 90-day low: AU$0.64

New 90-day low: AU$0.66

New 90-day low: AU$0.74

Cynata Therapeutics Limited Announces Phase 3 Osteoarthritis Clinical Trial Commences

Cynata Therapeutics Limited Announces Positive Efficacy Data from A Study of Cymerustm Mesenchymal Stem Cells

New 90-day high: AU$1.03

New 90-day high - AU$0.79

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven